Year: 2021
Type: review
Abstract: Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule comparable to PD-1 and CTLA-4 and a potential target for enhancing anti-cancer immune responses. LAG-3 is the third inhibitory receptor to be exploited in human anti-cancer immunotherapies, and it is considered a potential next-generation cancer immunotherapy target in human therapy, right next to PD-1 and CTLA-4. Unlike PD-1 and CTLA-4, the exact mechanisms of action of LAG-3 and its relationship with other immune checkpoint molecules remain poorly understood. This is partly caused by the presence of non-conventional signaling motifs in its intracellular domain that are different from other conventional immunoregulatory signaling motifs but with similar inhibitory activities. Here we summarize the current understanding of LAG-3 signaling and its role in LAG-3 functions, from its mechanisms of action to clinical applications.
DOI: 10.3390/ijms22105282
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,160
Awards: G1876127687, Desarrollo de nuevos linfocitos T y CAR antineoplásicos para terapias de transferencia celular, G2315758218, G2826120990, G2914298903, G3052694055, G3176542433, G329096338, G4325621580, G4666753673, G5844642162, G5904726733, Impacto de la inmunoterapia anti-PDL1/PD1 sobre las capacidades anti-tumorales de los linfocitos T humanos en diferentes estadíos de diferenciación, TranspoCART: ensayo clínico multicéntrico de fase I/II con células CART específicas de CD19 basadas en trasposones en pacientes con R/R LLA CD19+, G7432836071, G7487337063, G8172865061
OpenAlex ID: W3162437281
